In a recent preliminary study, afamelanotide (16 mg subcutaneous implant) along with Narrowband UVB has given promising results In Vitiligo – Here is the study reportVitiligo is a chronic skin disorder that affects millions of individuals worldwide. The condition is characterized by the …by SomapikaJune 21, 2023in Case StudiesEnglishVitiligo
World Vitiligo Day – 2023Vitiligo has a global prevalence where close to 0.5-2% of the world’s population suffers from it. While the …by SomapikaJune 16, 2023in Case StudiesEnglishVitiligo